Molecular Therapies of Cancer Scientific Program

癌症分子疗法科学计划

• 批准号: 8180819
• 负责人: JAMES K. WILLSON
• 金额: $ 2.37万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-03 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8180819
• 关键词: Behavior; Biological Markers; Biological Models; Cancer Center; Cancer Center Support Grant; Cell surface; Chemistry; Clinic; Clinical; Development; Diagnostic; Disease; Event; Genetic; Goals; Image; Individual; Link; Malignant Neoplasms; Malignant neoplasm of lung; Molecular; Nanotechnology; Pathogenesis; Patients; Pre-Clinical Model; Prevention; Research; Research Personnel; Role; Scientist; Series; Therapeutic; Tissue Model; Translational Research; Variant; anticancer research; base; cancer cell; cancer diagnosis; cancer imaging; cancer therapy; experience; human tissue; in vivo; novel; novel diagnostics; programs; response; tool; tumor

The Molecular Therapeufics of Cancer Program (MTCP) is a "translational research" effort interfacing basic scientists with clinicians specializing in cancer diagnosis and treatment. The program has deep strengths in lung cancer research and has used this experience to catalyze addifional research that links disease oriented teams and basic researchers. The MTCP also provides a major series of bridges through its interactions other Cancer Center Programs. The goals of the MTCP are to understand the molecular events (genetic and epigenefic) leading to cancer, as well as understanding the role of inter-individual genefic variation in developing and treating cancer, and use this informafion to provide a rafionale basis for developing novel diagnostic, prevention, and therapeutic strategies. Specifically the MTCP seeks to: ¿ Understand the molecular pathogenesis of cancers with a focus on human tissues and model systems with a particular emphasis on lung cancer. This includes both descripfion of the abnormalifies and demonstrating their funcfional relevance as biologic, therapeufic and diagnostic targets. ¿ Develop new cancer imaging and nanotechnology tools to deliver novel imaging agents and therapeufics to highlight these targets in vivo in preclinical model and later in the clinic. ¿ Develop molecular therapeutics including those involving or combined with radiafion targeted at the abnormalities found in studies of the molecular pathogenesis as well as the identificafion and use of specific cell surface markers characterisfic of certain cancers as therapeufic targets. ¿ Develop tumor molecular biomarkers that allow predicfion of clinical behavior and response to specific treatments of individual patients so that treatment can be "personalized." ¿ Use advances in the other Cancer Center Programs (Chemistry and Cancer, Cancer Cell Networks, and Development and Cancer) to inform each of these prior themes in a way that is unique to the Simmons Cancer Center and that will provide synergy of research efforts and facilitate translafion to the clinic at UTSW.

癌症分子治疗计划（MTCP）是一项“转化研究”工作， 科学家和专门从事癌症诊断和治疗的临床医生。该计划在以下方面具有深厚的优势： 肺癌研究，并利用这一经验来催化额外的研究， 面向团队和基础研究人员。MTCP还通过其 其他癌症中心项目的互动。 MTCP的目标是了解导致癌症的分子事件（遗传和表观遗传）， 以及了解个体间基因变异在癌症发展和治疗中的作用， 利用这些信息为开发新的诊断、预防和治疗方法提供理论基础。 战略布局具体而言，该方案力求： 了解癌症的分子发病机制，重点是人体组织和模型系统， 尤其是肺癌。这既包括对非正常化的确认， 它们作为生物、治疗和诊断靶点的功能相关性。 开发新的癌症成像和纳米技术工具，以提供新的成像剂和治疗剂 以在临床前模型和随后的临床中突出这些靶点。 开发分子疗法，包括那些涉及或结合放射治疗靶向 在分子发病机制的研究中发现的异常以及特异性 作为治疗靶点的某些癌症的细胞表面标志物。 开发肿瘤分子生物标志物，可以预测临床行为和对特定 对个别患者进行治疗，使治疗能够“个性化”。" ²利用其他癌症中心项目（化学与癌症、癌细胞网络和 发展和癌症），以一种独特的方式告知这些先前的主题，西蒙斯 癌症中心，这将提供研究工作的协同作用，并促进在 UTSW。